Monopar Therapeutics (NASDAQ:MNPR) Stock Price Expected to Rise, HC Wainwright Analyst Says

Monopar Therapeutics (NASDAQ:MNPR) had its price objective hoisted by HC Wainwright from $6.00 to $22.00 in a report issued on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Rodman & Renshaw assumed coverage on Monopar Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $50.00 target price for the company.

Monopar Therapeutics Trading Down 1.0 %

NASDAQ MNPR traded down $0.17 during trading on Monday, reaching $16.49. The company’s stock had a trading volume of 2,871 shares, compared to its average volume of 691,569. The stock has a market capitalization of $65.30 million, a PE ratio of -8.46 and a beta of 1.09. Monopar Therapeutics has a 1-year low of $1.37 and a 1-year high of $38.50. The business has a 50-day moving average price of $7.84 and a 200-day moving average price of $4.91.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.09. As a group, analysts expect that Monopar Therapeutics will post -1.93 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Karthik Radhakrishnan bought 1,550 shares of the business’s stock in a transaction on Monday, October 28th. The shares were bought at an average cost of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the acquisition, the chief financial officer now owns 1,550 shares in the company, valued at approximately $25,187.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 34.90% of the stock is owned by insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.